Q-omics provides the consensus-scored PRR30 profile across patient tissues and cancer cell-line models. PRR30 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, PRR30 is differentially expressed in 1, with the highest sampling consensus in THCA. Additionally, PRR30 RNA expression shows 6,478 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UVM, THCA, and STAD as cancer lineages where PRR30 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRR30 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRR30 survival associations across molecular data types. PRR30 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRR30 RNA expression–survival associations across cancer types. High PRR30 expression shows unfavorable associations in UVM, THCA, READ, SCLC, KIRC and UCS. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for PRR30 RNA expression.
This table summarizes PRR30 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for PRR30. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRR30 shows higher tumor expression in THCA. The THCA box plot shows higher PRR30 RNA expression in tumor versus normal tissue (log2 FC = +0.018, t-test p = .003).
This table shows molecular features associated with PRR30 in patient tissues and cancer cell lines. In patient samples, PRR30 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, PRR30 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
